• 1. Pd-catalyzed desulfitative arylation for the synthesis of 2,5-diarylated oxazole-4-carboxylates using dioxygen as the terminal oxidant
  Xiaodong Tang,Kai Yang,Liying Zeng,Qiang Liu,Huoji Chen Org. Biomol. Chem. 2017 15 8504
• 2. Carbonates: eco-friendly solvents for palladium-catalysed direct arylation of heteroaromatics
  Jia Jia Dong,Julien Roger,Cécile Verrier,Thibaut Martin,Ronan Le Goff,Christophe Hoarau,Henri Doucet Green Chem. 2010 12 2053

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenyl-1,3-oxazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Oxazoles Phenyl-1,3-oxazoles

Recent Advances in the Study of Ethyl 2-phenyl-1,3-oxazole-4-carboxylate (CAS: 39819-39-1) in Chemical Biology and Pharmaceutical Research

Ethyl 2-phenyl-1,3-oxazole-4-carboxylate (CAS: 39819-39-1) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This oxazole derivative serves as a key intermediate in the synthesis of various bioactive molecules, including antimicrobial, anti-inflammatory, and anticancer agents. Recent studies have explored its potential as a scaffold for designing novel therapeutics, leveraging its unique chemical properties and biological activity.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of ethyl 2-phenyl-1,3-oxazole-4-carboxylate derivatives as potent inhibitors of bacterial efflux pumps, a mechanism critical for addressing antibiotic resistance. The research team synthesized a series of analogs and evaluated their activity against multidrug-resistant Staphylococcus aureus (MRSA) strains. The lead compound exhibited a MIC (minimum inhibitory concentration) of 2 μg/mL, highlighting its potential as a candidate for further development.

In another groundbreaking study, researchers investigated the compound's role in modulating inflammatory pathways. Published in Bioorganic & Medicinal Chemistry Letters, the study revealed that ethyl 2-phenyl-1,3-oxazole-4-carboxylate derivatives could selectively inhibit COX-2 enzymes, reducing prostaglandin E2 (PGE2) production by 70% in vitro. This finding suggests its potential application in developing non-steroidal anti-inflammatory drugs (NSAIDs) with fewer side effects compared to traditional COX-2 inhibitors.

The compound's anticancer properties have also been a focus of recent research. A 2024 preprint on ChemRxiv detailed its ability to induce apoptosis in triple-negative breast cancer (TNBC) cells by disrupting mitochondrial membrane potential. The study employed molecular docking simulations to identify interactions with Bcl-2 family proteins, providing mechanistic insights into its pro-apoptotic effects. These findings open new avenues for targeted cancer therapies.

From a synthetic chemistry perspective, innovations in the production of ethyl 2-phenyl-1,3-oxazole-4-carboxylate have emerged. A green chemistry approach using microwave-assisted synthesis was reported in ACS Sustainable Chemistry & Engineering, achieving an 85% yield with reduced reaction time and solvent waste. This advancement addresses both economic and environmental concerns in pharmaceutical manufacturing.

Ongoing clinical trials are evaluating ethyl 2-phenyl-1,3-oxazole-4-carboxylate-based compounds for various indications. Phase I results for an antifungal derivative showed promising safety profiles, while preclinical data for a neuroprotective analog demonstrated blood-brain barrier permeability in animal models. These developments underscore the compound's translational potential across multiple therapeutic areas.

Future research directions include structure-activity relationship (SAR) studies to optimize pharmacokinetic properties and the development of prodrug formulations to enhance bioavailability. With its diverse biological activities and synthetic versatility, ethyl 2-phenyl-1,3-oxazole-4-carboxylate continues to be a valuable scaffold in drug discovery pipelines worldwide.

• 885273-19-8(4-Oxazolecarboxylicacid, 2-(3-methylphenyl)-, ethyl ester)
• 885272-98-0(4-Oxazolecarboxylicacid, 2-(3-fluorophenyl)-, ethyl ester)
• 78979-61-0(4-Oxazolecarboxylicacid, 2-(4-methoxyphenyl)-, ethyl ester)
• 391248-21-8(Ethyl 2-(4-Aminophenyl)-1,3-oxazole--carboxylate)
• 200400-76-6(Ethyl 2-(4'-Hydroxyphenyl)-1,3-oxazole-4-carboxylate)
• 132089-42-0(Ethyl 2-(4-fluorophenyl)oxazole-4-carboxylate)
• 78979-62-1(4-Oxazolecarboxylicacid, 2-(4-chlorophenyl)-, ethyl ester)
• 391248-23-0(Ethyl 2-(4-Bromophenyl)-1,3-Oxazole-4-Carboxylate)
• 132089-43-1(Ethyl 2-(3-chlorophenyl)oxazole-4-carboxylate)
• 885273-06-3(Ethyl 2-(3-Bromophenyl)Oxazole-4-Carboxylate)